Imfinzi vs. Opdivo

Imfinzi (durvalumab) and Opdivo (nivolumab) are monoclonal antibodies used to treat different types of cancer.

Imfinzi is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy; or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Opdivo is used to treat patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor; and to treat metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.

Side effects of Imfinzi and Opdivo that are similar include fatigue, constipation, decreased appetite, nausea, swelling of extremities, abdominal pain, musculoskeletal pain diarrhea/colitis, fever, shortness of breath, cough, and rash.

Side effects of Imfinzi that are different from Opdivo include urinary tract infection (UTI).

Side effects of Opdivo that are different from Imfinzi include itching, upper respiratory tract infection, vomiting, weakness, swelling, chest pain, joint pain, weight loss, irregular heartbeat, eye inflammation, infusion-related reactions, increased amylase, increased lipase, dizziness, numbness and tingling, skin peeling, skin redness, and psoriasis.

Both Imfinzi and Opdivo may interact with other drugs.

Common side effects of Imfinzi include:

• fatigue,
• musculoskeletal pain,
• constipation,
• decreased appetite,
• nausea,
• swelling of extremities,
• urinary tract infection,
• abdominal pain,
• diarrhea/colitis,
• fever,
• shortness of breath,
• cough, and
• rash.

Common side effects of Opdivo include:

• fatigue
• rash
• itching
• cough
• upper respiratory tract infection
• swelling of the extremities
• shortness of breath
• muscle pain
• decreased appetite
• nausea
• vomiting
• constipation
• diarrhea
• weakness
• swelling
• fever
• abdominal pain
• chest pain
• joint pain
• weight loss
• irregular heartbeat
• eye inflammation
• infusion-related reactions
• increased amylase
• increased lipase
• dizziness
• numbness and tingling
• skin peeling
• skin redness and
• psoriasis.

Imfinzi (durvalumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy; or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Opdivo (nivolumab) is a human monoclonal antibody used to treat patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor; and to treat metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.

Imfinzi may interact with other drugs. Tell your doctor all medications and supplements you use.

Opdivo may interact with other drugs. Tell your doctor all medications and supplements you use.

Administer Imfinzi in a dose of 10 mg/kg as an intravenous infusion over 60 minutes every 2 weeks.

The recommended dose of Opdivo depends on the condition being treated and whether Opdivo is being administered as a single agent or in combination with another drug.